New MRI dye could sharpen images of brain and body lesions

NCT ID NCT07472491

Recruiting now Diagnosis Sponsor: GE Healthcare Source: ClinicalTrials.gov ↗

First seen Mar 23, 2026 · Last updated May 30, 2026 · Updated 8 times

Summary

This study tests a new contrast agent called mangaciclanol for MRI scans in 640 adults with known or suspected brain or body lesions. The goal is to see if it improves image quality and lesion detection compared to a standard agent. Participants will receive both agents at different times for comparison.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNOWN OR HIGHLY SUSPECTED CENTRAL NERVOUS SYSTEM (CNS) LESION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Arensia Exploratory Medicine - Moldova - IMSP Spitalul Clinic Republican Timofei Mosneaga
RECRUITING

Chisinau, MD-2025, Moldova
LLC Todua Clinic
RECRUITING

Tbilisi, 0119, Georgia
LTD Israel-Georgian Medical Research Clinic Healthycore
RECRUITING

Tbilisi, 0112, Georgia
LTD New Hospitals
RECRUITING

Tbilisi, 0114, Georgia
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States

Conditions

Explore the condition pages connected to this study.

KNOWN OR HIGHLY SUSPECTED BODY (EXCLUDING CNS) LESION KNOWN OR HIGHLY SUSPECTED CENTRAL NERVOUS SYSTEM (CNS) LESION